Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Ceo-Two (potassium bitartrate / sodium bicarbonate)
- gefitinib
Interactions between your drugs
sodium bicarbonate gefitinib
Applies to: Ceo-Two (potassium bitartrate / sodium bicarbonate), gefitinib
ADJUST DOSING INTERVAL: Coadministration with drugs that elevate gastric pH such as H2-receptor antagonists and antacids may decrease the plasma concentrations of gefitinib. According to the manufacturer, the solubility of gefitinib is pH-dependent and decreases sharply between pH 4 and 6, becoming practically insoluble above pH 7. When gefitinib 250 mg was administered to healthy male volunteers (n=26) one hour following two oral 450 mg doses of ranitidine with sodium bicarbonate as needed to achieve a sustained gastric pH above 5.0, mean gefitinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 71% and 47%, respectively, compared to administration of gefitinib alone. High doses of short-acting antacids may have a similar effect if taken regularly in close proximity to gefitinib administration.
MANAGEMENT: The possibility of a diminished therapeutic response to gefitinib should be considered during coadministration with H2-receptor antagonists or antacids. If concomitant treatment is required, the manufacturer recommends administering gefitinib 6 hours before or 6 hours after an H2-receptor antagonist or antacid.
References (5)
- (2023) "Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals
- (2022) "Product Information. Apo-Gefitinib (gefitinib)." Apotex Inc
- (2023) "Product Information. Iressa (gefitinib)." AstraZeneca UK Ltd
- (2021) "Product Information. Iressa (gefitinib)." AstraZeneca Pty Ltd
- Tang W, Tomkinson H, Masson E (2017) "Effect of sustained elevated gastric pH levels on gefitinib exposure." Clin Pharmacol Drug Dev, 6, p. 517-23
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
MiraLAX
MiraLAX (polyethylene glycol) is used as a laxative to treat occasional constipation or irregular ...
Colace
Colace makes bowel movements softer and is used to treat or prevent constipation. Includes Colace ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Linzess
Linzess (linaclotide) is used to treat chronic idiopathic constipation, irritable bowel syndrome ...
Dulcolax
Dulcolax (bisacodyl) is a laxative used to treat constipation. Includes Dulcolax side effects ...
Metamucil
Metamucil is used for constipation, dietary fiber supplementation, irritable bowel syndrome
Amitiza
Amitiza (lubiprostone) is used to treat chronic constipation and irritable bowel syndrome with ...
Trulance
Trulance (plecanatide) is used to treat chronic idiopathic constipation (CIC) and irritable bowel ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.